STOCK TITAN
  1. Home
  2. News
  3. AKTX

Akari Therapeutics plc ADR (0.01 USD) - AKTX STOCK NEWS

Welcome to our dedicated page for Akari Therapeutics plc ADR (0.01 USD) news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics plc ADR (0.01 USD) stock.

Akari Therapeutics Plc (Nasdaq: AKTX) is a clinical-stage biopharmaceutical company developing innovative treatments for autoimmune and inflammatory diseases. The company's lead asset, nomacopan, is a bispecific recombinant inhibitor targeting complement C5 and leukotriene B4 (LTB4) pathways. This dual-action therapeutic is currently being investigated in a Phase 3 trial for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), a rare and serious complication with high mortality rates. Nomacopan has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA, as well as orphan drug designation from the European Commission.

Akari's pipeline also includes PAS-nomacopan, a long-acting version of the drug designed for the treatment of geographic atrophy (GA), a leading cause of blindness. PAS-nomacopan is in the final stages of pre-clinical development and aims to offer extended dosing intervals with potentially improved safety and efficacy compared to existing therapies.

The company's strategic focus recently expanded through a definitive merger agreement with Peak Bio Inc. (OTC: PKBO), expected to close in Q3 2024. This merger will create a robust pipeline featuring both Akari's autoimmune and inflammatory disease therapeutics and Peak Bio's antibody-drug conjugate (ADC) platform technology for cancer treatment.

Financially, Akari is focused on operational efficiency and value creation. The company has taken significant measures to reduce costs and secure funding, including a successful private placement raising approximately $7.6 million. Dr. Samir R. Patel, an experienced life sciences entrepreneur, has recently been appointed Interim CEO to lead the company through this transformative phase. Dr. Patel's compensation is solely equity-based, aligning his interests with those of the shareholders.

For more information, visit akaritx.com.

News

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Rhea-AI Summary
Akari Therapeutics, Plc (Nasdaq: AKTX) announces positive pre-clinical results for long-acting PAS-nomacopan as a potential treatment for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD). The company plans to submit an IND in 2024 for Phase 1 testing to evaluate safety and pharmacokinetics/pharmacodynamics (PK/PD). The development includes an advanced high yielding manufacturing process, supporting the program's progression into clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
clinical trial
-
News

Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Rhea-AI Summary
Akari Therapeutics, Plc announced that Chief Scientific Officer Miles Nunn will present a poster on the development of PASylated®-Nomacopan for the treatment of Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (dAMD) at the 4th Annual Dry AMD Therapeutic Development conference. The poster will be presented on November 15, 2023, at 3:00 pm ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
conferences clinical trial
-
News

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

Rhea-AI Summary
Akari Therapeutics announced financial results for the first half of 2023. The company's priority pipeline programs are on track, with enrollment in Phase 3 clinical trials expected to begin soon. Akari received orphan drug designation from the European Commission, adding to existing FDA designations. The company also strengthened its capabilities with new appointments. Akari's lead asset, nomacopan, is progressing well in development for various indications. The company is also advancing its long-acting PAS-nomacopan program for geographic atrophy. Akari's financial results show a net loss of approximately $3.0 million for the first half of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.19%
Tags
earnings
News

Akari Therapeutics to Present at Emerging Growth Conference

Rhea-AI Summary
Akari Therapeutics to participate in Emerging Growth Conference on October 4 and 5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences acquisition
-
News

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit

Rhea-AI Summary
Akari Therapeutics announces private placement of equity securities and receipt of UK R&D tax credit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
none
-
News

Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs

Rhea-AI Summary
Akari Therapeutics to host virtual event on October 19, 2023 to discuss potential treatment for HSCT-TMA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
conferences
News

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary
Akari Therapeutics regains compliance with minimum bid price requirement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.59%
Tags
none
-
News

Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials

Rhea-AI Summary
Akari Therapeutics establishes U.S. headquarters in Boston Seaport area to support expansion and clinical trials
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
clinical trial
-
News

Akari Therapeutics, Plc Announces ADS Ratio Change

Rhea-AI Summary
Akari Therapeutics, Plc (Nasdaq: AKTX) will change the ratio of its ADSs to ordinary shares from 1:100 to 1:2000 to regain compliance with Nasdaq minimum bid price requirement. Each ADS holder will exchange 20 ADSs for 1 new ADS. No change to underlying ordinary shares. Fractional entitlements will be sold and proceeds distributed to ADS holders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.4%
Tags
none
News

Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs

Rhea-AI Summary
Akari Therapeutics, Plc (Nasdaq: AKTX) appoints Beth-Anne Lang as Senior Vice President, Regulatory Affairs. Lang brings over 20 years of experience in regulatory strategy and drug development. She will focus on advancing Phase 3 clinical trials in pediatric and adult HSCT-TMA and the PAS-nomacopan program. Lang's track record includes successful drug approvals in the U.S. and globally, making her expertise valuable for Akari's urgent regulatory filings. Before Akari, Lang led regulatory strategy for rare disease therapeutics at Enzyvant Therapeutics and Horizon Therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
management

FAQ

What is the current stock price of Akari Therapeutics plc ADR (0.01 USD) (AKTX)?

The current stock price of Akari Therapeutics plc ADR (0.01 USD) (AKTX) is $0.97 as of December 20, 2024.

What is the market cap of Akari Therapeutics plc ADR (0.01 USD) (AKTX)?

The market cap of Akari Therapeutics plc ADR (0.01 USD) (AKTX) is approximately 26.5M.

What is the focus of Akari Therapeutics?

Akari Therapeutics focuses on developing innovative therapies for autoimmune and inflammatory diseases, including severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) and geographic atrophy (GA).

What is nomacopan?

Nomacopan is Akari's lead drug, a bispecific recombinant inhibitor targeting complement C5 and leukotriene B4 (LTB4) pathways. It is currently in Phase 3 clinical trials for treating HSCT-TMA.

What designations has nomacopan received?

Nomacopan has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA, as well as orphan drug designation from the European Commission.

What is PAS-nomacopan?

PAS-nomacopan is a long-acting version of nomacopan, currently in pre-clinical development for treating geographic atrophy (GA), a leading cause of blindness.

What are the recent developments at Akari Therapeutics?

Recent developments include a merger agreement with Peak Bio Inc., raising $7.6 million in a private placement, and appointing Dr. Samir R. Patel as Interim CEO.

What is the significance of the merger with Peak Bio?

The merger is expected to combine Akari's therapeutic pipeline with Peak Bio's ADC platform technology for cancer treatment, expanding the company's capabilities and market potential.

How is Dr. Samir R. Patel compensated?

Dr. Samir R. Patel's compensation as Interim CEO is solely equity-based, aligning his interests directly with those of Akari's shareholders.

What financial measures has Akari taken recently?

Akari has implemented a reduction-in-force to cut costs and has successfully raised $7.6 million through a private placement to fund its operations and strategic initiatives.

What is the timeline for the merger with Peak Bio?

The merger with Peak Bio is expected to close in the third quarter of 2024, subject to customary closing conditions and shareholder approvals.

Where can I find more information about Akari Therapeutics?

For more information, visit Akari Therapeutics' website at akaritx.com.

Stock AKTX logo
Akari Therapeutics plc ADR (0.01 USD)

Nasdaq:AKTX

AKTX Rankings

#5186 Ranked by Market Cap
N/A Ranked by Dividends

AKTX Stock Data

26.47M
20.19M
11.91%
0.51%
0.18%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON